Cabenuva ‘an important alternative’ to daily pill for adelescents
ViiV Healthcare, the HIV specialist majority owned by GSK, has announced week 96 and end of study results from the Phase I/II IMPAACT 2017 study, the first trial to evaluate a complete injectable long acting treatment regimen in adolescents living with HIV.
Results showed 94.4% of virologically suppressed adolescents aged 12 to 18 years or more, who switched from daily oral HIV treatment to long-acting cabotegravir and rilpivirine (CAB + RPV LA) every two months, maintained viral suppression at week 96, with at least 97% indicating a preference for injections over daily oral therapy at all weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze